Drug profile

The FDA adverse-event record for Subcutaneous Fluids

420 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Subcutaneous Fluids. See the species affected, top reactions, and outcomes below.

420
adverse-event reports
27.1%
death-coded share
Cat
most-reported species
108
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
420
Total Reports
114
Deaths Reported
27.1%
Death Rate

Active Ingredients

Subcutaneous Fluids

Administration Routes

SubcutaneousUnknownTopical

Species Affected

Cat 214
Dog 205
Rabbit 1

Most Affected Breeds

Domestic Shorthair 116
Domestic Longhair 29
Crossbred Canine/dog 19
Retriever - Labrador 16
Cat (unknown) 16
Domestic Mediumhair 14
Cat (other) 12
Terrier - Yorkshire 10
Retriever - Golden 10
Siamese 9

Most Reported Reactions

Vomiting 108
Anorexia 84
Lethargy (see also Central nervous system depression in 'Neurological') 74
Lethargy (see also Central nervous system depression in Neurological) 72
Ataxia 66
Death by euthanasia 61
Diarrhoea 60
Other abnormal test result NOS 58
Weight loss 54
Not eating 53
Death 50
Fever 47

Outcome Breakdown

Ongoing
147 (35.0%)
Outcome Unknown
87 (20.7%)
Recovered/Normal
68 (16.2%)
Euthanized
61 (14.5%)
Died
53 (12.6%)
Recovered with Sequela
4 (1.0%)

Subcutaneous Fluids Adverse Event Insights

420 reports name Subcutaneous Fluids; 114 recorded a death outcome (27.1% of reported events, not a population-level mortality rate). Active ingredient: Subcutaneous Fluids. Administration routes: Subcutaneous, Unknown, Topical.

By species: Cat (214 reports), Dog (205 reports), Rabbit (1 reports). By breed: Domestic Shorthair (116), Domestic Longhair (29), Crossbred Canine/dog (19).

Leading clinical signs: Vomiting (108), Anorexia (84), Lethargy (see also Central nervous system depression in 'Neurological') (74), Lethargy (see also Central nervous system depression in Neurological) (72). Outcome, 420 coded reports: Ongoing leads at 35.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.